Merck Frosst
Executive Summary
Company is spending $270 mil. to construct a plant in Kirkland, Ontario to manufacture Mevacor for Canada and selected European markets. Merck Frosst is among several companies expanding Canadian research and manufacturing operations in response to government actions to remove compulsory licensing and, in effect, extend marketing exclusivity ("The Pink Sheet" July 13, p. 6).